)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Jacobio Pharmaceuticals Group (1167) investor relations material
Jacobio Pharmaceuticals Group H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary29 Aug, 2025
Executive summary
Revenue reached RMB45.7 million for the six months ended June 30, 2025, driven by a milestone payment from the Allist Licensing Agreement, compared to nil in the prior year period.
Loss for the period narrowed significantly to RMB59.0 million from RMB169.1 million year-over-year, reflecting reduced R&D and administrative expenses.
Achieved NMPA market approval and launch of glecirasib for ≥2L NSCLC in China in May 2025, with strong clinical efficacy and safety data published.
Advanced a diversified oncology pipeline, including pan-KRAS, SHP2, BET, Aurora kinase A, p53 Y220C, iADC, and tADC programs, with global and China-based trials ongoing.
Entered a licensing agreement with Allist for commercialization and clinical development of glecirasib and sitneprotafib in Greater China, triggering milestone revenue.
Financial highlights
Revenue increased to RMB45.7 million from nil, attributable to the Allist Licensing Agreement milestone.
R&D expenses decreased 47.3% year-over-year to RMB93.2 million, mainly due to Allist funding pivotal trials.
Administrative expenses fell 12.4% to RMB18.6 million, reflecting cost controls and efficiency gains.
Net loss for the period was RMB59.0 million, a substantial improvement from RMB169.1 million in the prior year; adjusted loss was RMB56.7 million.
Gross profit reached RMB45.7 million, with no cost of revenue recognized.
Outlook and guidance
Focus on expanding the KRAS and iADC pipelines, leveraging allosteric inhibitor and iADC platforms for global leadership in oncology.
Continued investment in R&D and strategic collaborations to maximize clinical and commercial value.
Anticipated completion of key Phase I/II trials and further regulatory submissions in 2026.
Expects to utilize remaining IPO proceeds by end of 2025, with resource reallocation to early-stage drug discovery and development.
Glecirasib ex-China strategy
iADC/tADC platform competitive edge
Is current R&D spend sustainable for pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Jacobio Pharmaceuticals Group earnings date
H2 202523 Apr, 2026
Next Jacobio Pharmaceuticals Group earnings date
H2 202523 Apr, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Jacobio Pharmaceuticals Group Co., Ltd. is a Chinese biopharmaceutical company focused on innovative drug discovery and development. It concentrates on oncology and immunology, advancing a pipeline of targeted therapies and immune-oncology treatments. The company uses in-house research platforms and conducts clinical trials both domestically and internationally. The company is headquartered in Beijing, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage